The ACTIV-6 trial investigated the effectiveness of inhaled fluticasone furoate on mild-to-moderate COVID-19 cases and found it did not accelerate recovery or prevent clinical progression compared to a placebo. Interestingly, vaccinated participants showed slightly faster recovery when treated with the drug, while unvaccinated participants did not.
Late-stage results set up Cytokinetics heart drug to compete with Bristol
Late-stage results of Cytokinetics’ drug for a rare heart disease suggest it can compete with a similar treatment sold by Bristol Myers Squibb on efficacy
May 13, 2024